- Conditions
- Solid Tumor, Metastatic Bladder Cancer
- Interventions
- RX-3117
- Drug
- Lead sponsor
- Processa Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Duarte, California + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2881–2904
of 9,821
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Liver Cancer, Metastatic Cancer
- Interventions
- lyso-thermosensitive liposomal doxorubicin, radiofrequency ablation
- Drug · Procedure
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Esophageal Cancer, Gastric Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- cisplatin, edotecarin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Brain Tumors
- Interventions
- MRI scan
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- canfosfamide hydrochloride
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Tumors
- Interventions
- Liposome Encapsulated Mitoxantrone (LEM)
- Drug
- Lead sponsor
- INSYS Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 4
- States / cities
- Duarte, California • Tampa, Florida • Detroit, Michigan + 1 more
- Conditions
- Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, HepatoCellular Carcinoma, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma
- Interventions
- INCB099280
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Detroit, Michigan • Pittsburgh, Pennsylvania + 2 more
- Conditions
- Aggressive Systemic Mastocytosis, Mast Cell Leukemia, Systemic Mastocytosis
- Interventions
- Brentuximab vedotin
- Drug
- Lead sponsor
- Jason Robert Gotlib
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 2
- States / cities
- Stanford, California • Houston, Texas
- Conditions
- Adenoid Cystic Carcinoma
- Interventions
- Tretinoin
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck, Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck
- Interventions
- MK-3475 (neoadjuvant), Surgery, Intensity modulated radiation therapy, Image-guided radiation therapy, Cisplatin, MK-3475 (adjuvant), Peripheral blood
- Biological · Procedure · Radiation + 1 more
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • St Louis, Missouri • New York, New York
- Conditions
- Advanced Non Small Cell Lung Cancer
- Interventions
- ATL001, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Achilles Therapeutics UK Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Tampa, Florida • New York, New York
- Conditions
- Biliary Tract Cancer
- Interventions
- NUC-1031, Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- NuCana plc
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 773 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • Whittier, California • Aurora, Colorado + 23 more
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- vorinostat
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pancreatic Cancer
- Interventions
- fluorouracil, gemcitabine hydrochloride, brachytherapy, phosphorus P32, radiation therapy
- Drug · Radiation
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Tumors
- Interventions
- satraplatin and docetaxel
- Drug
- Lead sponsor
- Agennix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Osteosarcoma
- Interventions
- Cyclophosphamide and Sirolimus
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma
- Interventions
- Balstilimab, Zalifrelimab, Doxorubicin, Botensilimab
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Tumor, Cancer
- Interventions
- AZD6244
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- cMET Dysegulation Advanced Solid Tumors
- Interventions
- INC280
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Pancreatic Cancer
- Interventions
- BPM31510 Nanosuspension Injection, Gemcitabine
- Drug
- Lead sponsor
- BPGbio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 9
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Gilroy, California + 6 more
- Conditions
- Advanced Refractory Solid Tumors
- Interventions
- PL225B
- Drug
- Lead sponsor
- Piramal Enterprises Limited
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm of Gastrointestinal Tract, Genitourinary Neoplasms Malignancy and Gender Unspecified, Head and Neck Neoplasms, Melanoma, Malignant Neoplasm of Thorax
- Interventions
- Alisertib, Pazopanib
- Drug
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced Malignancy
- Interventions
- XL999
- Drug
- Lead sponsor
- John Sarantopoulos
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer
- Interventions
- Leflunomide
- Drug
- Lead sponsor
- Deborah Doroshow
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York